SB alters drug tests

Click to follow
The Independent Online
SmithKline Beecham said it has stopped administering placebos in two US trials on its carvedilol heart drug because tests have shown the drug is "unexpectedly" effective in reducing death rates.

SB shares rose by 7.5p to 490.5p after the announcement.